ArticleClinical rheumatology2025
Integration of metabolomics and genomics implicates a causality between 1398 blood metabolites and gout.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionMetabolic disorders represent a hallmark feature of gout. However, evidence on the causality of blood metabolites and gout remains lacking. We performed a Mendelian randomization (MR) analysis to systematically evaluate the causality from genetically proxied 1398 blood metabolites to gout.
methodGenome-wide association study (GWAS) data for 1398 blood metabolites were extracted from 8299 European subjects. The discovery stage was performed using gout data from FinnGen consortium R9 to initially explore causal associations between metabolites and gout. The significant associations identified in the discovery stage were validated in the replication stage employing gout GWAS data from the IEU database. Random-effect inverse variance weighted was chosen as the main method for causality analysis, with MR-Egger, weighted median, robust adjusted profile score, and maximum likelihood as complementary analysis methods. Then, a series of sensitivity analyses were performed.
resultsResults showed that there was a significant causal relationship between eight metabolites and gout, including 21-hydroxypregnenolone disulfate levels, carnitine levels, ethyl beta-glucopyranoside levels, gamma-glutamylglycine levels, glycine levels, glycine-to-alanine ratio, glycolithocholate sulfate levels, and propionylglycine levels. Colocalization analysis evidence strongly supported a causal relationship between 21-hydroxypregnenolone disulfate levels and carnitine levels and gout. In addition, four metabolic pathways were involved in the biological process of gout (carnitine synthesis, beta oxidation of very long-chain fatty acids, alanine metabolism, glutathione metabolism).
conclusionsThe current study provides evidentiary support for the causal relationship between eight blood metabolites and gout and identifies four significant metabolic pathways. These findings hold the potential to inform future research, clinical interventions, and therapeutic strategies for gout.
Indexed as
Identifiers
40153197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.